-
ApolloBio’s HPV Therapeutic Vaccine VGX-3100 Gets NMPA Green Light for Clinical Trial
•
ApolloBio Corp., a joint stock company of China’s leading cephalosporin manufacturer Jincheng Pharmaceutical Group Co., Ltd. (SHE: 300233), has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for VGX-3100. This drug, hailed as the world’s first therapeutic vaccine for human papillomavirus (HPV), is…
-
Beijing’s Apollobio Receives NMPA Approval for HPV Therapeutic Vaccine VGX-3100
•
Beijing’s Apollobio, has announced that the National Medical Products Administration (NMPA) has granted market approval for its innovative therapeutic vaccine VGX-3100. This vaccine, which targets HPV-16/18 related anal precancerous lesions, is a significant advancement in the treatment landscape for conditions associated with Human Papillomavirus (HPV). The vaccine’s approval follows a…
-
ApolloBio Partners with Baidu Health to Enhance Marketing of IgM Nano Immunoglobulin Spray
•
Guangzhou-based biotech ApolloBio has signed a strategic cooperation agreement with Baidu Health. Under this partnership, Baidu will provide innovative digital support to enhance ApolloBio’s marketing activities, particularly for protective products related to infectious respiratory diseases. This includes an IgM nano immunoglobulin protective spray, known as a ‘liquid mask’ type nasal…
-
Inovio and ApolloBio Announce Positive Phase III Data for VGX-3100 Vaccine
•
US-based Inovio Pharmaceuticals (NASDAQ: INO) and China-based ApolloBio Corp. (NEEQ:430187) have announced positive data from the Phase III Reveal 2 study for the DNA therapeutic vaccine VGX-3100 (known as ABC-3100 in China). The two firms are co-developing VGX-3100 under a 2018 licensing deal, with ApolloBio holding development and commercialization rights…
-
ApolloBio Corp. Initiates Pre-Clinical Study for ABC-5100 Nanobody Against COVID-19
•
ApolloBio Corp. (NEEQ:430187) announced the initiation of a pre-clinical study for its novel broad-spectrum anti-COVID-19 nanobody, ABC-5100. The drug is designed to prevent or provide early treatment for SARS-CoV-2 coronavirus infections. Pre-Clinical Study DetailsABC-5100 has demonstrated efficacy against various variants of concern (VOCs), including Omicron. The nanobody can be administered…
